STOCKHOLM, Sweden--(BUSINESS WIRE)--Medivir (STO:MVIRB)
Decision to focus research activities to the Huddinge facility
Decision on SEK 224.5 m rights issue
Tibotec filed an application to start clinical trials on the hepatitis C project
Phase III study on Lipsovir® (ME-609) against labial herpes started in July. Just over 50% of patients in the study were treated during the second half-year, according to plan.
